Loading...

Kindred Biosciences

DB:17K
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
17K
DB
$343M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
17K Share Price and Events
7 Day Returns
1%
DB:17K
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
6.9%
DB:17K
-7.4%
DE Biotechs
-5.6%
DE Market
17K Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kindred Biosciences (17K) 1% 6.8% -9.6% 6.9% 142.2% -27.6%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 17K outperformed the Biotechs industry which returned -7.4% over the past year.
  • 17K outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
17K
Industry
5yr Volatility vs Market

Value

 Is Kindred Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kindred Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €7.826.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kindred Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kindred Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:17K PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.60
NasdaqCM:KIN Share Price ** NasdaqCM (2019-04-24) in USD $8.82
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kindred Biosciences.

DB:17K PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:KIN Share Price ÷ EPS (both in USD)

= 8.82 ÷ -1.60

-5.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kindred Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Kindred Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Kindred Biosciences's expected growth come at a high price?
Raw Data
DB:17K PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
46.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kindred Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kindred Biosciences's assets?
Raw Data
DB:17K PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.69
NasdaqCM:KIN Share Price * NasdaqCM (2019-04-24) in USD $8.82
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:17K PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:KIN Share Price ÷ Book Value per Share (both in USD)

= 8.82 ÷ 2.69

3.28x

* Primary Listing of Kindred Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kindred Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Kindred Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kindred Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kindred Biosciences expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
46.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kindred Biosciences expected to grow at an attractive rate?
  • Kindred Biosciences's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Kindred Biosciences's earnings growth is expected to exceed the Germany market average.
  • Kindred Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:17K Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:17K Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 46.1%
DB:17K Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 48.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:17K Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:17K Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 137 24 38 3
2022-12-31 108 0 25 4
2021-12-31 62 -12 -19 4
2020-12-31 27 -42 -53 6
2019-12-31 11 -39 -61 6
DB:17K Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -45 -50
2018-09-30 1 -38 -44
2018-06-30 -30 -39
2018-03-31 -27 -34
2017-12-31 -22 -31
2017-09-30 -21 -27
2017-06-30 -20 -25
2017-03-31 -18 -23
2016-12-31 -19 -22
2016-09-30 -20 -23
2016-06-30 -22 -25
2016-03-31 -23 -26

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kindred Biosciences's earnings are expected to grow significantly at over 20% yearly.
  • Kindred Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:17K Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Kindred Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:17K Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.86 0.95 0.77 2.00
2022-12-31 0.40 0.96 0.05 3.00
2021-12-31 -0.46 -0.18 -0.62 3.00
2020-12-31 -1.32 -0.98 -1.62 6.00
2019-12-31 -1.58 -1.41 -1.70 6.00
DB:17K Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.60
2018-09-30 -1.49
2018-06-30 -1.39
2018-03-31 -1.29
2017-12-31 -1.23
2017-09-30 -1.17
2017-06-30 -1.17
2017-03-31 -1.13
2016-12-31 -1.13
2016-09-30 -1.16
2016-06-30 -1.24
2016-03-31 -1.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kindred Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Kindred Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kindred Biosciences has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kindred Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kindred Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kindred Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Kindred Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kindred Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kindred Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kindred Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:17K Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.97 -49.69 26.50 26.40
2018-09-30 0.64 -43.98 22.10 23.79
2018-06-30 -38.83 18.76 21.19
2018-03-31 -34.36 16.05 19.23
2017-12-31 -30.88 13.99 17.67
2017-09-30 -26.96 11.57 16.03
2017-06-30 -24.75 10.32 14.91
2017-03-31 -22.93 9.13 14.20
2016-12-31 -22.50 8.31 13.86
2016-09-30 -23.11 7.79 14.93
2016-06-30 -24.52 7.86 16.21
2016-03-31 -26.46 7.92 18.04
2015-12-31 -27.13 7.85 19.41
2015-09-30 -27.50 7.98 19.64
2015-06-30 -26.48 8.23 18.36
2015-03-31 -27.70 8.81 19.01
2014-12-31 -27.14 8.54 18.69
2014-09-30 -22.73 7.17 15.64
2014-06-30 -17.87 5.08 12.84
2014-03-31 -10.16 2.68 7.50
2013-12-31 -4.21 1.08 3.14
2012-12-31 -0.48 0.18 0.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kindred Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kindred Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kindred Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kindred Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kindred Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kindred Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kindred Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kindred Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kindred Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kindred Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Kindred Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kindred Biosciences Company Filings, last reported 3 months ago.

DB:17K Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 91.21 0.00 73.93
2018-09-30 104.43 0.00 91.63
2018-06-30 115.76 0.00 109.93
2018-03-31 76.16 0.00 70.82
2017-12-31 84.68 0.00 81.02
2017-09-30 92.93 0.00 86.30
2017-06-30 76.27 0.00 73.55
2017-03-31 71.14 0.00 65.14
2016-12-31 57.68 0.00 56.76
2016-09-30 62.53 0.00 60.48
2016-06-30 67.22 0.00 61.15
2016-03-31 71.14 0.00 68.57
2015-12-31 76.37 0.00 73.04
2015-09-30 81.65 0.00 83.59
2015-06-30 87.74 0.00 89.74
2015-03-31 93.40 0.00 94.59
2014-12-31 99.02 0.00 101.03
2014-09-30 104.91 0.00 106.43
2014-06-30 109.68 0.00 112.44
2014-03-31 58.49 0.00 60.53
2013-12-31 63.28 0.00 65.33
2012-12-31 0.87 0.00 0.94
  • Kindred Biosciences has no debt.
  • Kindred Biosciences has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kindred Biosciences has sufficient cash runway for 1.3 years based on current free cash flow.
  • Kindred Biosciences has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 33.4% each year.
X
Financial health checks
We assess Kindred Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kindred Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kindred Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kindred Biosciences dividends.
If you bought €2,000 of Kindred Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kindred Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kindred Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:17K Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:17K Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kindred Biosciences has not reported any payouts.
  • Unable to verify if Kindred Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kindred Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kindred Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kindred Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kindred Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kindred Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kindred Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Chin
COMPENSATION $2,119,784
AGE 51
TENURE AS CEO 6.5 years
CEO Bio

Dr. Richard Chin, M.D. is a Co-Founder of Kindred Biosciences, Inc. and has been its Chief Executive Officer and served as its President since October 2012 until October 2018 and served as its Interim Chief Financial Officer UNTIL July 28, 2017. Dr. Chin served as the Chief Executive Officer of The Institute for OneWorld Health from 2008 to 2011. Dr. Chin served as Chief Executive Officer and President of Oxigene Inc. from July 2006 to October 22, 2008. He served as Secretary of Oxigene, Inc. He served as the Senior Vice President of Medical Affairs of Elan Corporation Limited and served as its Vice President of Medical Affairs since June 24, 2004. Dr. Chin served as Senior Vice President and Head of Global Development for Elan Corporation, plc from May 2005 to 2006 and as Senior Vice President and Head of Global Medical Affairs of Elan from June 2004 to May 2005. Dr. Chin has worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. He has also held various clinical and scientific roles for Genentech, Inc. from March 1999 to June 2004, including Head of Clinical Research for Genentech Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech. He began his career in July 1997 at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. He has been a Director of Kindred Biosciences, Inc since 2012. He has been a Director of Galena Biopharma, Inc. since April 23, 2009. He serves as a Director and Member of Scientific Advisory Board of Genmedica Therapeutics S.L. Dr. Chin serves as a Director of The Institute for OneWorld Health. He serves as Member of Scientific Advisory Board at G2B Pharma, Inc. He serves as Member of Advisory Board at Essia Health, Inc. He serves as Director at Balance Therapeutics, Inc. Dr. Chin serves on the board of directors for Immunocellular Therapeutics and Galena Biopharma. He has been Member of Scientific Advisory Board at Serenus Biotherapeutics, Inc. since October 2014. He serves as Member of Advisory Board at Immusoft Corporation and served as its Director. He serves as Member of Advisory Board at Scribes STAT. He served as a Director at ImmunoCellular Therapeutics, Ltd. from March 16, 2012 to June 26, 2015. He served as a Director of Oxigene Inc. from August 2005 to October 22, 2008. He served on the Adjunct Clinical Faculty of Stanford University School of Medicine. Dr. Chin is a Board Certified Internist with extensive expertise in drug development. He has overseen over 40 Investigational New Drug (IND) Applications for new molecular entities and new indications, as well as eight New Drug Applications (NDAs)/Biologic License Applications (BLAs), and has authored a major textbook on clinical trial medicine. Dr. Chin is also an Associate Professor at the UCSF School of Medicine and has authored several textbooks on clinical trial medicine. He has authored several textbooks on clinical development and teaches drug development at UCSF School of Medicine, where he serves as Adjunct Associate Professor. Dr. Chin serves on the board of directors of several biotechnology companies, including Immunocellular Therapeutics and Galena Biopharma. He holds Bachelors of Arts in Biology, magna cum laude, from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes Scholarship. Dr. Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California.

CEO Compensation
  • Richard's compensation has increased whilst company is loss making.
  • Richard's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Kindred Biosciences management team in years:

1.5
Average Tenure
54.5
Average Age
  • The average tenure for the Kindred Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Richard Chin

TITLE
Co-Founder
COMPENSATION
$2M
AGE
51
TENURE
6.5 yrs

Denise Bevers

TITLE
Co-Founder
COMPENSATION
$2M
AGE
51
TENURE
0.5 yrs

Wendy Wee

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
65
TENURE
1.8 yrs

Hangjun Zhan

TITLE
Chief Scientific Officer
AGE
58
TENURE
1.3 yrs

Katja Buhrer

TITLE
Vice President of Corporate Development & Investor Relations
Board of Directors Tenure

Average tenure and age of the Kindred Biosciences board of directors in years:

3
Average Tenure
64
Average Age
  • The tenure for the Kindred Biosciences board of directors is about average.
Board of Directors

Richard Chin

TITLE
Co-Founder
COMPENSATION
$2M
AGE
51
TENURE
7.3 yrs

Denise Bevers

TITLE
Co-Founder
COMPENSATION
$2M
AGE
51
TENURE
0.5 yrs

Ervin Veszprémi

TITLE
Independent Director
COMPENSATION
$191K
AGE
59
TENURE
6.2 yrs

Raymond Townsend

TITLE
Independent Director
COMPENSATION
$191K
AGE
73
TENURE
5.4 yrs

Herbert Montgomery

TITLE
Independent Director
COMPENSATION
$191K
AGE
75
TENURE
3 yrs

Ernie Mario

TITLE
Director
COMPENSATION
$99K
AGE
79
TENURE
1 yrs

Joe McCracken

TITLE
Director
AGE
64
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
23. Jan 19 Buy Park West Asset Management LLC Company 18. Jan 19 18. Jan 19 741,840 €8.36 €6,205,306
28. Sep 18 Sell Raymond Townsend Individual 25. Sep 18 26. Sep 18 -3,000 €11.75 €-34,008
22. Jun 18 Buy Park West Asset Management LLC Company 20. Jun 18 20. Jun 18 820,336 €8.20 €6,730,201
X
Management checks
We assess Kindred Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kindred Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. In addition, the company develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-014 to treat gastric ulcers in horses; epoCat, a feline recombinant erythropoietin for the management of anemia in cats; KIND-011, a monoclonal antibody that targets sick or septic foals; and KIND-509, an antibody for canine inflammatory bowel disease. Further, it is developing KIND-015 for the management of clinical signs associated with equine metabolic syndrome and anti-tumor necrosis factor in septic foals; KIND-502, an IgE antibody that targets the canine counterpart of the human target for allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; and various antibodies that target cytokines involved in atopic dermatitis, as well as interleukin antibodies and canine checkpoint inhibitors. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Details
Name: Kindred Biosciences, Inc.
17K
Exchange: DB
Founded: 2012
$306,204,646
38,855,154
Website: http://www.kindredbio.com
Address: Kindred Biosciences, Inc.
1555 Bayshore Highway,
Suite 200,
Burlingame,
California, 94010,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM KIN Common Stock Nasdaq Capital Market US USD 12. Dec 2013
DB 17K Common Stock Deutsche Boerse AG DE EUR 12. Dec 2013
Number of employees
Current staff
Staff numbers
146
Kindred Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:37
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.